The costs of psoriasis medications.

Dermatology and Therapy
Anssi MustonenRisto Tuominen

Abstract

Psoriasis is a chronic disease, which contributes to the economic burden on health care. The distribution of psoriasis medication costs and the quality of life in these patients has been estimated to be around 20% of total costs. To estimate the economic distribution of medications and the impact of multiple treatment options on a patient's quality of life. The study was based on 236 Finnish psoriasis patients. The Finnish Social Insurance Institution had databases for all psoriasis related medications purchased. Each purchase, during the 1-year study period (1 October 2009-30 September 2010), was recorded and analyzed. The dermatological quality-of-life index was collected from the medical records. Total medication costs were <euro>1,083 per year per patient. Topical treatments were the most often purchased medication and they comprised 18% of the total medication costs. Ten percent of the patients needed 3 or more medication changes during the 1-year study period. Biologics were used only by 5% of patients, but they produced 67% of total medication costs. Patients needing various treatments had higher medication costs and a poorer quality of life. A small number of patients generated a great sum of medication costs partly due...Continue Reading

References

Dec 1, 1996·British Journal of Rheumatology·O Kaipiainen-Seppänen
Jul 14, 2001·Journal of the European Academy of Dermatology and Venereology : JEADV·S P Raychaudhuri, E M Farber
Aug 29, 2003·Expert Opinion on Pharmacotherapy·Steven R FeldmanJeffrey Vallee
Jun 22, 2005·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Karin BergerMatthias Augustin
Oct 4, 2005·Journal of the American Academy of Dermatology·Joel M GelfandTara Rolstad
Jan 26, 2006·Expert Opinion on Pharmacotherapy·Drew W Miller, Steven R Feldman
Feb 10, 2006·The Journal of Dermatological Treatment·Daniel J PearceSteven R Feldman
Feb 18, 2006·Dermatology : International Journal for Clinical and Investigative Dermatology·S SohnM Augustin
Aug 11, 2006·Journal of the European Academy of Dermatology and Venereology : JEADV·J M CarrascosaC Ferrándiz
Sep 19, 2007·Archives of Dermatology·Tamar NijstenRobert S Stern
Aug 30, 2008·Therapeutics and Clinical Risk Management·Gl ColomboS Chimenti
Aug 30, 2008·Clinics in Dermatology·Marc Alexander Radtke, Matthias Augustin
Jan 20, 2010·Archives of Dermatology·Vivianne Beyer, Stephen E Wolverton
Feb 19, 2010·The British Journal of Dermatology·R J B DriessenE M G J De Jong
Mar 20, 2010·Journal of the European Academy of Dermatology and Venereology : JEADV·N MeyerJ P Ortonne
Jul 9, 2011·Expert Opinion on Pharmacotherapy·Jonathan P StaidleSteven R Feldman
Apr 25, 2012·Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·Matthias AugustinMarc Alexander Radtke
Sep 22, 2012·PharmacoEconomics·Giovanna RahoLuigi Naldi
Nov 23, 2012·International Journal of Dermatology·Adrian R LevyCharles W Lynde
Apr 6, 2013·European Journal of Dermatology : EJD·Kalle MattilaRisto Tuominen

❮ Previous
Next ❯

Citations

Aug 17, 2014·BMC Health Services Research·Anssi MustonenRisto Tuominen
May 29, 2014·Dermatology and Therapy·A MustonenR Tuominen

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsies

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.